


Advocacy | Education | Networking Presents



22<sup>nd</sup> - 23<sup>rd</sup> October 2021 | 06:00 pm - 09:30 pm

#### PROGRAM DIRECTOR



Dr. Nilesh Lokeshwar
Consultant Medical Oncology,
Asian Cancer Institute,
Mumbai

#### **ORGANISING SECRETARY**




Dr. Tejinder Singh
Sr. Consultant Medical Oncologist,
Apollo Hospital,
Navi Mumbai



Dr. Adwaita Gore
Sr. Consultant Medical Oncologist,
Prince Aly Khan Hospital &
Zen Multi Speciality Hospital, Mumbai





22<sup>nd</sup> - 23<sup>rd</sup> October 2021 | 06:00 pm - 09:30 pm

#### Dear Colleagues,

Anti-PD1/PD-L1 and driver mutation directed therapies have been a revolution in the field of advanced lung cancer by improving the prognosis. This has givenhope to a large population of patients who are potential long-term survivors.

Nevertheless, with the overlapping approvals of IO treatment and new targeted therapies for oncogenic altered mutation it has become difficult to navigate which treatment will benefit whom. Optimal treatment selection using validated biomarkers are key to improving the patient outcomes.

Keeping in mind this practice changing evidence in lung cancer and fast progressing research that are providing new answers, we at Onconxt invite you for "Lung Cancer: Leaps and Bounds". This meeting will be held on 22<sup>nd</sup> & 23<sup>rd</sup> October 2021 on virtual platform.

We aim to review the landscape of impactful and complex evidence in Lung Cancer through focused talks and interactive panel discussions.

We request you to share your opinions, dilemmas and if possible clinical scenarios which you want us to get discussed during this meeting. You can write to us on <a href="mailto:onconxtedu@gmail.com">onconxtedu@gmail.com</a>

We have various sponsorship opportunities for pharma partners and we request you to get in touch with our event manager and discuss the same.

With Best Regards,

**Dr. Nilesh Lokeshwar** 

**Dr. Tejinder Singh** 

**Dr. Adwaita Gore** 







# **Scientific Program**

	The below session is supported by Novartis	
06:00 - 06:15 pm	Therapeutic landscape in ALK positive mNSCLC Speaker: Dr. Shrikant Tiwari	
06:15 - 06:30 pm	Capmatinib: Unlocking the unMET need in METex14 skipping NSCLC.  Speaker: Dr. Kaushal Patel	
	The below session is supported by Eli Lilly	
06:30 - 06:40 pm	RELAYing RELAY: Speaker: Dr. Ashish Singh	
06:40 - 07:00 pm	Clinical case based panel discussion on "Personalized treatment approaches for EGFRm+ NSCLC patients":  Moderator: Dr. Ashish Kaushal  Panelists: Dr. Vamsi Krishna, Dr. Krupa Shankar S	
Session 1	Shooting for the moon in EGFRm NSCLC	
	Chairpersons: Dr. B. K. Smruti, Dr. Shuaib Zaidi, Dr. Shyam Aggarwal	
07:00 - 07:10 pm	Pushing the TKI boundaries: Adjuvant strategies in EGFR mutated NSCLC Speaker: Dr. Shefali Sardana	





# **Scientific Program**

07:10 - 07.20 pm Maximize the survival distance : The

javelin throw with 1L treatment in

EGFRm+ advanced NSCLC Speaker: Dr. Itesh Khatwani

07:20 - 07:30 pm Shining through the leaves:

Shining through the leaves:
Outcomes in uncommon EGFR+

mutations NSCLC

Speaker: Dr. Rakesh Pinninti

#### **Chairpersons:**

Dr. Govind Babu, Dr. Digamber Behera

07:30 - 08:00 pm

Cased Based Discussion:

EGFRm+ adjuvant NSCLC and

uncommon mutation in advanced

**NSCLC** 

Moderator: Dr. Bharat Rangarajan

Panelists: Dr. Prashant Perumudu,


Dr. Vikas Talereja, Dr. Kiran Kattimani,

Dr. Prakash Devede, Dr. Bharat Vaswani,

Dr. Virendra Tiwari, Dr. Salil Patkar,

Dr. Shubham Jain, Dr. Nikhil Kalyani





# Scientific Program

Session 2	Oncogenic drivers of change in advanced NSCLC	
	Chairpersons: Dr. J. B. Sharma, Dr. Sadaishivudu Gundeti	
	The below session is supported by Pfizer	
08:00 - 08:10 pm	We need to t-ALK+: Considerations for choosing the first line ally in advanced NSCLC  Speaker: Dr. Nikhil Ghadyalpatil	
08:10 - 08:20 pm	Reaching the sanctuary site: Options for ALK+ NSCLC patients with brain metastases  Speaker: Dr. Vijay Agarwal	
08:20 - 08:30 pm	Proving the METtle : Coping with mutations  Speaker: Dr. Narayanan Prasad	
	Chairpersons: Dr. K Samba Sivaiah, Dr. Jyoti Wadhwa	


08:30 - 09:00 pm

Driver mutations in advanced NSCLC:
Case Based Discussion focusing on
ALK+ and MET+ mutations
Moderator: Dr. Priya Tiwari
Panelists: Dr. Sujith M, Dr. Rohit Pai,
Dr. Chetan Deshmukh, Dr. Vivek Agarwala,
Dr. Kumar Prabhash, Dr. B. S. Sainath,
Dr. Pinaki Mahato, Dr. Arvind Kumar,
Dr. Charu Bahl

Click the link below to register <a href="https://www.riverroute.in/llb">https://www.riverroute.in/llb</a>







# **Scientific Program**

	The below session is supported by Astrazeneca	
09:00 - 09:10 pm	New Practices in the Management of Early - Stags Lung Cancer Speaker: Dr. Bharat Bhosale	
09:10 - 09:30 pm	Case based discussion: Optimizing Management of ES - SCLC Moderator: Dr. S. S. Alurkar Panelists: Dr. Stalin Chowdary Bala, Dr. Srinivas B. J., Dr. Anita Ramesh, Dr. Uma Dangi, Dr. Adwaita Gore, Dr. Salil Patkar	





	D.,
lentitic .	<b>Program</b>
	i i ogi aiii

Role of Dual I-O therapy in treatment 06:00 - 06:30 pm of 1L mNSCLC Speaker- Dr. Tejinder Singh

Bridging the gap in lung cancer Session 3

**Chairpersons:** 

Dr. S. S. Alurkar, Dr. S. H. Advani

Adding a feather to the bio of io: 06:30 - 06:40 pm Winning the game in ES SCLC

Speaker: Dr. Akhil Kapoor

06:40 - 06.50 pm Team work makes dreamwork: IO as a Important Component of Multimodal Therapy for Stage III unresectable NSCLC

Speaker: Dr. Bhuvan Chugh


Potential Biomarkers for Predicting 06:50 - 07:00 pm

Immunotherapy Response: Finding the

Needle in the Haystack

Speaker: Dr. Vanitha Norohna





Scientific Program

**Chairpersons:** 

Dr. D. C. Doval, Dr. Loknath Dasappa

07:00 - 07:30 pm

Case Based Discussion: Assessing role of biomarkers for predicting immunotherapy response

Moderator: Dr. T. Raja

Panelists: Dr. Rakesh Reddy Boya,

Dr. Kaushal Patel, Dr. Ravi Wategonkar, Dr. M V Chandrakanth, Dr. Nikhil Pande,

Dr. Sanju Cyriac, Dr. Jacob George

Chairperson: Dr. S. H. Advani

07:30 - 08:00 pm

Role of first line Pembrolizumab in mNSCLC Patients

Speaker: Dr. Vijay Patil

Session 4

Choosing an IO to bet on for the gladiatorial battle in NSCLC colosseum

Chairpersons:

Dr. K. Pavithran

08:00 - 08:15 pm


Hit it hard : optimal tactics for PDL1+ve

advanced NSCLC

Speaker: Dr. Rakesh Roy







# Scientific Program

08:15 - 08:30 pm Connecting the dots : Immunotherapy in EGFRm+ NSCLC

Speaker: Dr. Nirmal Raut

08:30 - 08:45 pm Doubling the fight: IO-IO on song in

advanced NSCLC

Speaker: Dr. Amit Rauthan

#### **Chairpersons:**

Dr. B. K. Mishra, Dr. Dharmesh Soneji

08:45 - 09:15 pm Case Based Discussion focusing on role of IO in EGFR+ NSCLC and patient

selection for 1L IO+IO combination in

advanced NSCLC

Moderator: Dr. Randeep Singh

Panelists: Dr. Devendra Pal,

Dr. Ravi Tippeswamy, Dr. Bharat Bhosale,

Dr. Ghanshyam Biswas, Dr. Chakor Vora,

Dr. Krupa Shankar S, Dr. Nilesh Lokeshwar

09:15 - 09:30 pm | Closing Remarks





Virtual Event Managed By

# rivezzoute®

■ Leaders in Streaming Modules

# Sarika Barne

Webinar Manager, River Route Event, Mumbai

Mobile: +91 99301 94266 | E-mail: rrcgsarika@gmail.com

Click for Registration: https://www.riverroute.in/llb

